Home / Stocks / MRK

Merck & Co. (MRK, Pharmaceuticals) Stock Valuation & Fair Value Quality business with a solid forward outlook

Merck & Co. (MRK, Pharmaceuticals) trades at a blended P/E of 29.7, about 111% above its historical normal valuation, with a forward growth estimate of 37.3% and a PEG of 0.80. Analysts' one-year estimates have been hit 82% of the time.

DATA AS OF 2026-08-21
Blended P/E
29.7
Normal P/E
14.0
PEG
0.80
Fwd growth
37.3%
Div yield
2.3%
RSI (14)
66.0
Neutral

The Street vs SeerForecast

Wall Street's mean price target for MRK is $137.73 across 26 analysts, 9.7% below the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: quality business with a solid forward outlook. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been quality business with a solid forward outlook since 2026-06-03.

Price and rating by weekClose moved +19.3 percent from 2026-06-03 to 2026-08-17, with 0 rating changes over 21 recorded weeks.2026-06-03: Quality business with a solid forward outlook, close 113.88 (recalculated)2026-06-10: Quality business with a solid forward outlook, close 118.24 (recalculated)2026-06-14: Quality business with a solid forward outlook, close 118.20 (recalculated)2026-06-16: Quality business with a solid forward outlook, close 115.17 (recalculated)2026-06-21: Quality business with a solid forward outlook, close 113.87 (recalculated)2026-07-02: Quality business with a solid forward outlook, close 129.56 (recalculated)2026-07-06: Quality business with a solid forward outlook, close 126.78 (recalculated)2026-07-09: Quality business with a solid forward outlook, close 125.07 (recalculated)2026-07-12: Quality business with a solid forward outlook, close 123.54 (recalculated)2026-07-13: Quality business with a solid forward outlook, close 124.03 (recalculated)2026-07-14: Quality business with a solid forward outlook, close 120.78 (recalculated)2026-07-20: Quality business with a solid forward outlook, close 124.40 (recalculated)2026-07-22: Quality business with a solid forward outlook, close 127.47 (recalculated)2026-07-25: Quality business with a solid forward outlook, close 131.07 (recalculated)2026-07-27: Quality business with a solid forward outlook, close 130.76 (recalculated)2026-07-31: Quality business with a solid forward outlook, close 130.20 (recalculated)2026-08-03: Quality business with a solid forward outlook, close 130.202026-08-07: Quality business with a solid forward outlook, close 128.58 (recalculated)2026-08-10: Quality business with a solid forward outlook, close 128.582026-08-14: Quality business with a solid forward outlook, close 135.84 (recalculated)2026-08-17: Quality business with a solid forward outlook, close 135.841141362026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 16.1+15%Quality business with a solid forward outlook
2026-06-10P/E 16.5+17%Quality business with a solid forward outlook
2026-06-14P/E 16.5+17%Quality business with a solid forward outlook
2026-06-16P/E 16.5+17%Quality business with a solid forward outlook
2026-06-21P/E 16.5+17%Quality business with a solid forward outlook
2026-07-02P/E 17.7+26%Quality business with a solid forward outlook
2026-07-06P/E 18.4+31%Quality business with a solid forward outlook
2026-07-09P/E 18.4+31%Quality business with a solid forward outlook
2026-07-12P/E 17.7+26%Quality business with a solid forward outlook
2026-07-13P/E 17.7+26%Quality business with a solid forward outlook
2026-07-14P/E 17.7+26%Quality business with a solid forward outlook
2026-07-20P/E 22.9+63%Quality business with a solid forward outlook
2026-07-22P/E 22.9+63%Quality business with a solid forward outlook
2026-07-25P/E 24.0+71%Quality business with a solid forward outlook
2026-07-27P/E 24.0+71%Quality business with a solid forward outlook
2026-07-31P/E 24.3+73%Quality business with a solid forward outlook
2026-08-03P/E 24.4+74%Quality business with a solid forward outlook
2026-08-07P/E 24.4+74%Quality business with a solid forward outlook
2026-08-10P/E 24.6+75%Quality business with a solid forward outlook
2026-08-14P/E 26.4+88%Quality business with a solid forward outlook
2026-08-17P/E 26.5+89%Quality business with a solid forward outlook
2026-08-21P/E 29.7+111%Quality business with a solid forward outlook ← now

Earnings moves: MRK moved more than the options market implied in 0 of 1 recent tracked reports.

Frequently asked questions

Is Merck & Co. stock overvalued?

At a blended P/E of 29.7 versus its historical normal P/E of 14.0, Merck & Co. trades about 111% above its typical valuation, with a PEG of 0.80 on 37.3% forward growth. tickerseer currently rates it quality business with a solid forward outlook.

What is Merck & Co.'s fair value and PEG?

Merck & Co. trades at a blended P/E of 29.7 against a historical normal P/E of 14.0, a PEG of 0.80, and a forward growth estimate of 37.3%.

Has tickerseer's rating of Merck & Co. changed?

tickerseer's rating has been quality business with a solid forward outlook since 2026-06-03.

What is the analyst price target for Merck & Co.?

The mean Wall Street price target for Merck & Co. is $137.73 across 26 analysts, 9.7% below the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track MRK free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.